Cosmo NVCMOPF +0.67%79 Buyback Yield % is -1.07 as of Jul. 05, 2026. GuruFocus rates CMOPF with a GF Score™ of 79/100 and a GF Value™ of $50.39 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 292 Drug Manufacturers companies, Cosmo NV ranks worse than 53.77% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Cosmo NV's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CMOPF vs LLY, JNJ, ABBV: Buyback Yield % Comparison
For the Drug Manufacturers - General subindustry, Cosmo NV's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cosmo NV Buyback Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cosmo NV's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Cosmo NV's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cosmo NV (CMOPF) has a Buyback Yield % of -1.07 as of Jul. 05, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Cosmo NV and its competitors. According to the industry distribution chart, Cosmo NV ranks #157 out of 292 companies in the Drug Manufacturers industry, placing it in the top 53.8%.
Is Cosmo NV's Buyback Yield % too high?
Cosmo NV's current Buyback Yield % is -1.07. Based on the distribution chart, Cosmo NV ranks #157 out of 292 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Cosmo NV has a GF Score™ of 79/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cosmo NV's Buyback Yield % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Cosmo NV ranks #157 out of 292 companies for Buyback Yield %. This places Cosmo NV in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Cosmo NV and its competitors. Cosmo NV's current Buyback Yield % is -1.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cosmo NV stock overvalued right now?
Based on GuruFocus' analysis, Cosmo NV (CMOPF) is currently considered Significantly Overvalued. The stock's GF Value™ is $50.39, compared to a current price of $82.60 — trading 63.9% above its estimated fair value. The current Buyback Yield % is -1.07. Cosmo NV's overall GF Score™ is 79/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Cosmo NV (CMOPF), the current Buyback Yield % is -1.07 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cosmo NV (CMOPF) Overvalued in 2026?
Based on GuruFocus' analysis, Cosmo NV stock appears to be overvalued.
The current stock price of $82.60 is trading 63.9% above its estimated GF Value™ of $50.39.
GuruFocus considers Cosmo NV to be Significantly Overvalued.
Key valuation signals for CMOPF:
Buyback Yield %: -1.07
GF Value™: $50.39 vs. price of $82.60 (63.9% above fair value)
No single metric tells the full story. See the CMOPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cosmo NV is is a life sciences company. The company is focused on MedTech AI, dermatology, gastrointestinal diseases, and contract development and manufacturing (CDMO). The company designs, develops, and manufactures solutions to address critical medical needs. Its technologies are trusted by international pharmaceutical and MedTech companies and reach patients and healthcare providers around the world. The product pipeline includes Eleview, GI Genius, Winlevi, Lialda, Uceris, and others.
79GF Score
Get the complete analysis for CMOPF
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CMOPF has been successfully added to your 
